IL21 and neoplasm: Studies have found that IL-21 hinders tumor development, especially during early stages [50]. Additionally, more recent studies using mouse models have demonstrated that combining an immune checkpoint blockade, such as anti PD-L1, with IL-21 administration increased antitumor activity, characterized by increased CD8+ T cell proliferation and by increased infiltration by, and memory of, effector T cells [50].